Particular bacteria from the gut microbiota metabolize levodopa (l-dopa), reducing bioavailability of the drug for treating Parkinson’s disease.
References
Sampson, T. R. et al. Cell 167, 1469–1480.e12 (2016).
Papavasiliou, P. S. et al. N. Engl. J. Med. 286, 8–14 (1972).
Bedarf, J. R. et al. Genome Med. 9, 39 (2017).
Hashim, H. et al. PLOS One 9, e112330 (2014).
Fasano, A. et al. Mov. Disord. 28, 1241–1249 (2013).
Zhu, H. et al. Sci. Rep. 6, 27779 (2016).
Whitfield, A. C. et al. ACS Chem. Neurosci. 5, 1192–1197 (2014).
Zimmermann, M. et al. Nature 570, 462–467 (2019).
Zimmermann, M. et al. Science 363, 6427 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Jameson, K.G., Hsiao, E.Y. A novel pathway for microbial metabolism of levodopa. Nat Med 25, 1195–1197 (2019). https://doi.org/10.1038/s41591-019-0544-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-019-0544-x
- Springer Nature America, Inc.
This article is cited by
-
Mitigating gut microbial degradation of levodopa and enhancing brain dopamine: Implications in Parkinson’s disease
Communications Biology (2024)
-
An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson’s disease participants
Nature Communications (2023)